B-Cell CLL/lymphoma 7A (BCL7A) (Middle Region) Peptide
-
- Target See all BCL7A products
- BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
- Protein Region
- Middle Region
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB)
- Sequence
- QENSSNSSPA PEPNSAVPSD GTEAKVDEAQ ADGKEHPGAE DASDEQNSQS
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-BCL7A Antibody(ARP57508_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
- Background
-
This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma. The N-terminal segment involved in the translocation includes the region that shares a strong sequence similarity with those of BCL7B and BCL7C. Two transcript variants encoding different isoforms have been found for this gene.
Alias Symbols: BCL7
Protein Interaction Partner: RELB,RELB,SMARCA2
Protein Size: 231 - Molecular Weight
- 25 kDa
- Gene ID
- 605
- NCBI Accession
- NM_020993, NP_066273
- UniProt
- Q4VC05
-